PDC*line Pharma Presents Primary Clinical Results From Phase I/II …
Dec 14, 2024 · PDC*lung01, in combination with pembrolizumab, demonstrates the potential to provide meaningful clinical benefit compared to pembrolizumab alone in stage IV Non-Small Cell Lung Cancer patients with PD-L1 ≥ 50% and is associated with mild safety profile.
Bicycle Therapeutics Announces Data Updates Across Zelenectide ...
Dec 14, 2024 · Topline combination data for zelenectide pevedotin plus pembrolizumab in first-line metastatic urothelial cancer demonstrated a 60% overall response rate, in line with existing therapies Dose selection and topline data from Phase 2/3 Duravelo-2 trial planned for 2H 2025 Heavily pretreated breast ...
Aflibercept 8 mg met primary endpoint in phase III study and ...
Dec 17, 2024 · Approximately 90% of aflibercept 8 mg patients were extended to every 8-week dosing and maintained their interval through 36 weeks. Aflibercept 8 mg demonstrated rapid and robust reduction of fluid in the retina, as measured by changes in central subfield thickness
Epirium Bio Announces FDA Clearance of Investigational New …
Dec 23, 2024 · MF-300 Phase 1 Patient Screening Commencing. Expected First Patient Dosed in Q1 2025. SAN DIEGO, CA, USA I December 23, 2024 I Epirium Bio, Inc. (Epirium), a biopharmaceutical company advancing medicines for neuromuscular and fibrotic diseases, is pleased to announce two significant milestones that mark a new chapter for the Company. The U.S. Food and Drug Administration (FDA) has cleared the ...
China's National Medical Products Administration (NMPA) …
Jan 8, 2025 · – First regimen to be approved in China to demonstrate superiority to platinum-containing chemotherapy for the treatment of locally advanced or metastatic urothelial cancer, the standard of care for nearly 40 years 1 – NMPA approval based on the global Phase 3 EV-302 trial (also known as KEYNOTE-A39) where the treatment combination significantly improved overall survival and progression ...
REGENXBIO Presents Positive Data from the Phase II Study of …
Oct 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Duvakitug positive phase 2b results demonstrate best-in-class …
Dec 17, 2024 · PARIS, France and Parsippany, NJ, USA I December 17, 2024 I Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD ...
FDA approves Zepbound® (tirzepatide) as the first and only …
Dec 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Sumitomo Pharma America Announces U.S. FDA Approval of …
Dec 23, 2024 · – GEMTESA ® is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH – . MARLBOROUGH, MA, USA I December 23, 2024 I Sumitomo Pharma America, Inc. (SMPA) announced today that the U.S. Food and Drug Administration (FDA) has approved GEMTESA ® (vibegron), a beta-3 (β 3) adrenergic receptor agonist, dosed once ...